Consortium Consortium
 Euripides Europe Consortium

QuicklinksQuicklinks
Objectives Objectives
The Project The Project
Impact Impact


LoginMembers
Login Login


SEVENTH FRAMEWORK PROGRAMME
The Group - Consortium - The University of Manchester

The University of Manchester
Wolfson Molecular Imaging Centre
27 Palatine Road
M20 2TR
Withington, Manchester

United Kingdom

 Homepage



Project Leader


Dr. Marie-Claude Asselin Dr. Marie-Claude Asselin
Phone: +44-(0)161-275 0068 
Fax: +44-(0)161-275 0003 
E-Mail to Dr. Marie-Claude Asselin Contact  
 



Project Staff


Dr. Gavin Brown
Synthetic chemist / Radiolabelling 
E-Mail to Dr. Gavin Brown Contact  

Dr. Adam McMahon
Analytical chemist / Metabolites analysis & quality control 
E-Mail to Dr. Adam McMahon Contact  

Dr. Julian Matthews
Methodologist / HRRT instrumentation & reconstruction 
E-Mail to Dr. Julian Matthews Contact  

Prof. Dr. Karl Herholz
Neurologist / Director of WMIC  
E-Mail to Prof. Dr. Karl Herholz Contact  


Institute Presentation


The Wolfson Molecular Imaging Centre (WMIC) is a newly integrated research institute of The University of Manchester that focuses on PET studies in Oncology and Neuroscience with methodological support. The centre is located at one of Europe's biggest cancer treatment hospitals, the Christie Hospital, and collaborates with the three main University Hospitals: Hope, Manchester Royal Infirmary and Wythenshawe.

The WMIC is a purpose-built centre for PET-based molecular imaging and has a GE PET Trace cyclotron, 23 synthesis hotcells of which 8 meet GMP standards for the manufacture of radiolabelled PET tracers.
The clinical suite comprises 2 human PET scanners, a PET/CT scanner and the HRRT brain scanner which is the highest performance camera in the UK with intrinsic 2.5mm spatial resolution, and a bioanalysis laboratory with state-of-the-art equipment for blood and metabolites assays.
The centre also houses a cell culture laboratory and a Quad HIDAC PET scanner for pre-clinical studies. Oncology studies commenced in June 2006 and brain studies in September 2006.
The WMIC was granted an MHRA license for the production and administration of [18F]- and [11C]-labelled compounds to humans in December 2006 and performed its first in-house radioligand brain PET scan in April 2007 with (R)-[11C]PK11195 as part of a study on neuroinflammation in dementia.


The University of Manchester